14.03.2005 15:37:00
|
MORNING UPDATE: Man Securities Inc. issues alerts for TWX, ERES, NUE,
CHICAGO, March 14 /PRNewswire/ -- Man Securities issues the following Morning Update at 8:30 AM EST with new PriceWatch Alerts for key stocks.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/MANSECLOGO )
Before the open... PriceWatch Alerts for TWX, ERES, NUE, LIN, and BMC, Market Overview, Today's Economic Calendar, and the Quote Of The Day.
QUOTE OF THE DAY
"In general, rising interest rates are not necessarily a bad thing for the market if they reflect a strengthening economy, but if they reflect higher inflation, then that could present a problem for the stock market." -- Michael Sheldon, chief market strategist, Spencer Clarke.
New PriceWatch Alerts for TWX, ERES, NUE, LIN, and BMC... PRICEWATCH ALERTS - HIGH RETURN COVERED CALL OPTIONS ----------- -- Time Warner Inc. Last Price 17.50 - JUL 17.00 CALL OPTION@ $1.20 -> 4.3 % Return assigned* -- Eresearchtechnology Inc. Last Price 11.53 - JUN 10.00 CALL OPTION@ $2.15 -> 6.6 % Return assigned* -- Nucor Corp. Last Price 62.55 - JUL 55.00 CALL OPTION@ $10.30 -> 5.3 % Return assigned* -- Linens N Things Inc. Last Price 22.65 - JUL 22.50 CALL OPTION@ $1.80 -> 7.9 % Return assigned* -- BMC Software Inc. Last Price 15.83 - AUG 15.00 CALL OPTION@ $1.80 -> 6.9 % Return assigned*
* To learn more about how to use these alerts and for our FREE report, "The 18 Warning Signs That Tell You When To Dump A Stock ", go to: http://www.investorsobserver.com/mu18
(Note: You may need to copy the link above into your browser then press the [ENTER] key)
** For the FREE report, "Is Your Investment Portfolio Disaster Proof? - Insights, Stocks, And Strategies." go to: http://www.investorsobserver.com/FREEDP
NOTE: All stocks and options shown are examples only. These are not recommendations to buy or sell any security.
NEWS LEADERS AND LAGGARDS
So far today, Endo Pharmaceuticals, International Business Machines, and Ascential Software lead the list of companies with the most news stories while OfficeMax and Genworth Financial are showing a spike in news. The Walt Disney Co., Marriott International, and Cemex SA de CV have the highest srtIndex scores to top the list of companies with positive news while American International Group and Alcatel lead the list of companies with negative news reports. AutoZone has popped up with a high positive news sraIndex score.
For the FREE article titled, "Earnings Season Decoded - An Essential 15 Point Checklist For Finding Winning Stocks." go to: http://www.wallstreetsecretsplus.com/go/freemu/
MARKET OVERVIEW
Overseas markets are looking strong, as 12 of the 15 that we track are currently higher with the cumulative average return standing at plus 0.140 percent. The Japanese government surprised investors by revising its Gross Domestic Product (GDP) data for the October-December period. After the revision, Japan's GDP showed slight expansion instead of a slight narrowing. The new GDP grew 0.1 percent from the July-September quarter. Japan's economy grew at an annualized expansion of 0.5 percent, the earlier report showed a 0.5 percent decline. The surprising revision up was attributed to revisions in inventories and government consumption. This revised data still indicates that Japan was in a technical recession for half of 2004.
The April contract on sweet crude oil fell $1.23 a barrel, a 2.3-percent drop in trading on Friday. This morning, crude oil has continued its decline, dipping 30 cents to $54.13 a barrel.
Be prepared for the investing week ahead with Bernie Schaeffer's FREE Monday Morning Outlook. For more details and to sign up, go to: http://www.investorsobserver.com/freemo
DYNAMIC MARKET OPPORTUNITIES
With a 7% increase in 2004, global drug sales experienced the slowest year for growth since 1998. In total, sales hit US$550 billion, with a massive 45% coming from North America. The news comes as drug/biotech companies endure a fierce amount of additional pressure from the Food & Drug Administration following several high-profile drug catastrophes such as Merck's painkiller Vioxx and Biogen and Elan's multiple sclerosis drug Tysabri. In addition, a shortage of new drugs on the market is hurting profit margins at some companies. Unsurprisingly, China boasts the fastest-growing drug market, with sales soaring 28% last year to US$9.5 billion. The data comes courtesy of IMS Health, which goes on to note that China will enjoy the fastest growth rate for the next four years, with the compound annual figure reaching 13%-16%. That's significantly higher than the rest of the world, which will muster up 6% to 9% drug sales growth. The world's biggest-selling drug in 2004 was Pfizer's cholesterol drug Lipitor, which posted global sales of US$12 billion last year. Merck's cholesterol drug Zocor finished second, with US$5.9 billion in sales, while Bristol-Myers Squibb's anti-clotting product Plavix ended third, with sales of US$5 billion. While drug sales slowed, one area that experienced solid growth was advertising spending. The U.S. presidential and Summer Olympics contributed to spending rising almost 10% in 2004 - the best year since 2000 - as the total amount spent hit US$141.1 billion. TNS Media Intelligence reports that of 17 subsectors, 16 enjoyed increases last year, with only national spot radio ads seeing a decline. Online ad spending was the biggest gainer, with a 20% spike. By company, General Motors boosted its advertising with a massive 17.5% increase to US$2.8 billion. But Proctor & Gamble took the honors for greatest amount spent with a 7.4% rise to US$2.9 billion.
Receive incisive economic/market commentary, profitable advice and access to a network of leading investment exports. Simply follow this link: http://www.investorsobserver.com/agora2
TODAY'S ECONOMIC CALENDAR No major economic news today.
Actively track stocks with Quote.com's QCharts and get the real time quotes and streaming technical charts you need to keep up with the market. For your free 30-day trial go to: http://www.investorsobserver.com/MUQuote1
Man Securities Inc. is one of the world's leading option order execution firms. Man's in-house broker team offers a level of personal service and experience unavailable from no-frills discount brokers. To improve your understanding of option pricing get Man's FREE "Margin/Option Wizard software at: http://www.investorsobserver.com/mancd. Member CBOE/NASD/SPIC. CRD# 6731
This Morning Update was prepared with data and information provided by:
InvestorsObserver.com - Better Strategies for Making Money -> For Investors With a Sense of Humor. Only $1 for your first month plus seven free bonuses worth over $420, see: http://www.investorsobserver.com/must
Quote.com QCharts- Real time quotes and streaming technical charts to keep you up with the market. Analyze, predict, and stay ahead. for a Free 30 day trial go to: http://www.investorsobserver.com/MUQuote2
247profits.com: You'll get exclusive financial commentary, access to a global network of experts and undiscovered stock alerts. Register NOW for the FREE 247profits e-Dispatch. Go to: http://www.investorsobserver.com/agora
Schaeffer's Investment Research - Sign up for your FREE e-weekly, Monday Morning Outlook, Bernie Schaeffer's look ahead at the markets. Sign Up Now http://www.investorsobserver.com/freemo
PowerOptionsPlus - The Best Way To Find, Compare, Analyze, and Make Money On Options Investments. For a 14-Day FREE trial and 5 FREE bonuses go to: http://www.investorsobserver.com/poweropt
All stocks and options shown are examples only. These are not recommendations to buy or sell any security and they do not represent in any way a positive or negative outlook for any security. Potential returns do not take into account your trade size, brokerage commissions or taxes which will affect actual investment returns. Stocks and options involve risk and are not suitable for all investors and investing in options carries substantial risk. Prior to buying or selling options, a person must receive a copy of Characteristics and Risks of Standardized Options available from Sharon at 800-837-6212 or at http://www.cboe.com/Resources/Intro.asp. Privacy policy available upon request.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nucor Corp.mehr Nachrichten
25.11.24 |
S&P 500-Titel Nucor-Aktie: So viel hätten Anleger mit einem Investment in Nucor von vor einem Jahr verloren (finanzen.at) | |
18.11.24 |
S&P 500-Titel Nucor-Aktie: So viel Gewinn hätte ein Investment in Nucor von vor 10 Jahren eingebracht (finanzen.at) | |
11.11.24 |
S&P 500-Titel Nucor-Aktie: So viel Gewinn hätte ein Nucor-Investment von vor 5 Jahren abgeworfen (finanzen.at) | |
06.11.24 |
Optimismus in New York: Letztendlich Gewinne im S&P 500 (finanzen.at) | |
06.11.24 |
Zuversicht in New York: S&P 500 präsentiert sich am Mittwochnachmittag fester (finanzen.at) | |
06.11.24 |
Handel in New York: S&P 500 zeigt sich am Mittag fester (finanzen.at) | |
06.11.24 |
Optimismus in New York: S&P 500-Börsianer greifen zum Handelsstart zu (finanzen.at) | |
04.11.24 |
S&P 500-Titel Nucor-Aktie: So viel Gewinn hätte ein Nucor-Investment von vor 3 Jahren eingefahren (finanzen.at) |
Analysen zu Nucor Corp.mehr Analysen
Aktien in diesem Artikel
Nucor Corp. | 145,62 | -0,22% |
Indizes in diesem Artikel
NASDAQ Comp. | 19 218,17 | 0,83% | |
S&P 500 | 6 032,38 | 0,56% | |
S&P 600 SmallCap | 935,46 | -0,94% | |
S&P 100 | 2 902,89 | 0,68% | |
NYSE US 100 | 17 376,20 | -0,02% |